Tuesday, November 17, 2026

CoreTissue BioEngineering accelerates medical innovation in knee ligament reconstruction by raising a total of approximately 600 million yen!

CoreTissue BioEngineering has raised a total of approximately 600 million yen in funding. NIHON HAM and Mitsui Sumitomo Insurance Capital participated as new shareholders, and additional investment was received from existing shareholders.
Currently, after conducting a corporate clinical trial of a tissue-regenerated ligament for anterior cruciate ligament reconstruction of the knee, the company is continuing a pilot study to evaluate the safety of the product. With this financing, the company plans to accelerate its business by preparing for clinical trials and establishing commercial production technology for U.S. expansion.

CoreTissue BioEngineering Raises New Funding of 600 Million Yen

CoreTissue BioEngineering Corporation (headquartered in Tsurumi-ku, Yokohama; Yoji Shirokura, Representative Director; hereinafter "CTBE") has raised a total of approximately 600 million yen in funding.

Two new shareholders, MSIVC2025V Investment Limited Partnership, whose unlimited liability partners are Nippon Ham Corporation and Mitsui Sumitomo Insurance Capital Co.

In addition, additional investments were received from existing shareholders, "Waseda Innovation Fund No.3 Investment Business Partnership" and "Waseda Investment Limited Partnership" with WELL INVESTMENT CORPORATION as unlimited liability partner, "MMA Investment Limited Partnership" with MORE MANAGEMENT CORPORATION as unlimited liability partner, and "NextG Investment Limited Partnership" with KSP Inc. as unlimited liability partner. Ltd. as unlimited liability partner, and "NextG Investment Limited Partnership" with KSP Inc. as unlimited liability partner.

CTBE is continuing a pilot study to evaluate the safety of a tissue-regenerative ligament (CT-ACL001) for use in reconstructive surgery of the anterior cruciate ligament of the knee, after conducting a first-in-human (FIH, the first use of a developed product in patient care) study last December in a corporate clinical trial.

With this financing, the company plans to advance preparations for clinical trials in the U.S. with the aim of developing business in the U.S. and to accelerate its business by obtaining feasibility of mass production technology for commercial production of developed products.

New investor comments

Fumio Maeda, Executive Vice President, Executive Vice President, Nippon Ham Co.
We believe that CTBE's efforts will give new value and role to livestock-derived resources in the form of medical devices, and contribute to the realization of performance, health, and further inspiration for athletes and sports enthusiasts. Nippon Ham has formulated a new R&D strategy, "Proteinnovation," for fiscal 2025, with a policy of focusing on the healthcare/medical and upcycling domains as new businesses.
Through our support to CTBE, we hope to contribute to the development of the sports medicine field through advanced utilization of livestock resources.

Takuya Shimazaki, Manager, Investment Department, Mitsui Sumitomo Insurance Capital Co.
Many people who have experienced an anterior cruciate ligament knee injury have undergone reconstructive surgery using their own tendon. And will their own performance return to pre-injury levels? What will I do if I tear it again? CTBE offers a new option that is a world apart from the conventional methods by applying its proprietary decellularization and sterilization technologies.
We have invested in this project in the hope that the success of the ongoing clinical trials in Japan and the initiatives in North America will help solve the 800,000 patient pains that are estimated to occur annually around the world. We will strive to overcome the obstacles in front of us one by one and realize our big dream of providing medical devices from Japan on a global scale!

About CoreTissue BioEngineering, Inc.

CoreTissue BioEngineering is a medical device startup based in Tsurumi-ku, Yokohama, Japan, that was spun out of Waseda University in 2016.
Using the technology developed by Kiyotaka Iwasaki, Faculty of Science and Engineering, Waseda University, which enables decellularization* of even thick tissues and freeze-drying/sterilization technology that maintains strength and allows easy rehydration, we have commercialized our first pipeline of tissue-regenerative ligaments (medical devices) for use in reconstructive surgery on the anterior cruciate ligament of the knee We are the world's pioneer in this field.

(Note) Decellularization (technology): Technology that removes cellular components, etc. that may cause immune reactions from animal tissues and creates tissues that regenerate their own tissues using them as scaffolds when transplanted into the body.

name of companyCoreTissue BioEngineering Inc.
EstablishmentNovember 2016
Location301, Life Science Research Center, 1-1-43 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, Japan
representativeYoji Shirokura
Business OverviewDevelopment, manufacturing and sales of medical devices based on decellularization technology
uniform resouce locatorhttps://www.coretissue.com/

PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
SourceCTBE
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。